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A TROPHOBLAST-SPECIFIC 8i-glycopro-
tein (TSG) (also referred to as SP-],
PAPP-C, PSBG or PSbG) was first
identified immunochemically in the serum
of pregnant women and placental tissue
(Tatarinov & Masyukevich, 1970; Bohn,
1971; Lin et al., 1974). Subsequently,
TSG was discovered in the serum of
patients with trophoblastic (Tatarinov
et al., 1974) and testicular tumours
(Tatarinov et al., 1975; Johnson et al.,
1977) and in non-trophoblastic malig-
nancies (Horne et al., 1976; Tatarinov &
Sokolov, 1977) and the frequency ofraised
levels of TSG was compared with HCCG in
these tumour groups (Bagshawe et al.,
1978; Seppala et al., 1978; Searle et al.,
1978; Tatarinov et al., 1976; Johnson et al.,
1977; Wuirz et al., 1979).
This study will present our recent data
on the clinical application of TSG assays
in patients with trophoblast and non-
trophoblast tumours.
Sera were obtainedfrompatients attend-
ing in three centres: Moscow Cancer
Center, U.S.S.R.; International Agency
for Research on Cancer, Lyon, France;
and the National Cancer Institute,
Bethesda, U.S.A., during the period 1973-
1977. 91 patients had hydatidiform moles
or gestational trophoblast tumours, 197
patients had various malignant tumours.
In addition sera were obtained from .90
healthy adult blood donors (Table I).
Serum levels of TSG were measured by
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radioimmunoassay as described pre-
viously (Tatarinov & Sokolov, 1977). The
sensitivity of the double-antibody radio-
immunoassay for TSG was -1 ng/ml; the
lowest measurable serum level ofTSG was
3 ng/ml.
Monospecific antisera to TSG (anti-
TSG) were prepared in rabbits as described
previously (Tatarinov & Masyukevich,
1970). Donkey anti-rabbit y-globulin
(anti-RGG) was purified from commercial
antisera prepared at the Gamaleya Insti-
tute of Epidemiology and Microbiology,
Moscow, U.S.S.R.
TSG was isolated from pooled pregnancy
sera by a combination of methods already
described (Bohn, 1971; Lin et al., 1974).
The protein fraction prepared by chroma-
tography with KM-32 cellulose was puri-
fied further by isoelectrofocusing. The
resulting fraction (pl 4.05) was used to
prepare 1251-labelled TSG. Its purity was
controlled immunologically by disc electro-
phoresis, using as comparison a sample of
pregnancy-specific 3i-glycoprotein (SP-1;
Bohn, 1971) provided by Dr Sizaret
(International Agency for Research on
Cancer, Lyon, France).
TSG was labelled with 1251 (Tatarinov
& Sokolov, 1977). 041 ml of 01M phos-
phate-buffered saline (PBS, pH 7-6) con-
taining 30 Hug of TSG was added to 0-1 ml
of PBS containing 041 mg of chloramine-T
and 2 mCi carrier-free Na1251 with a speci-
fic activity of 106 mCi/ml (Leningrad,
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TABLE I. Serum TSG in control donors and in patients with various trophoblastic and
non-trophoblastic tumours
Diagnosis
Control adult male and female
Hydatidiform mole
Post-molar trophoblast tumours
Uterine choriocarcinoma
Tumour of the testis
Cancei of the lung
breast
digestive tract
miscellaneous
Total
* Mediastinal teratoma.
No.
patients
90
15
28
48
45
32
40
34
46
398
U.S.S.R.). The mixture was shaken and
left to stand for 75 sec. Then 01 ml of
PBS containing 0-25 ng sodium meta-
bisulphite and 0 075 nml of 10% Nal were
added. The free and bound 1251 were
separated by column chromatography
using Sephadex G-50 (1.2 x 15 cm) equili-
brated with PBS. 0-5ml fractions were
collected into glass tubes containing
0-05 ml 5% BSA. The test samples of
labelled TSG were stored with 1% BSA
and 0.05% sodium azide at 2°C. Labelled
fractions containing 95% or more of the
label in TSG were used for radioimmuno-
assay.
The immunoadsorbent was prepared
with Sepharose 4B activated by cyanogen
bromide. After washing of the activated
Sepharose by 1 1 of 0-5M PBS at pH 8*0,
purified anti-rabbit y-globulin (anti-RGG)
obtained from donkey anti-RGG was
added to the activated gel in amounts of
10 mg of anti-RGG per 1 g of dry Sepha-
rose. The mixture was mixed slowly for
16 h at 4°C. The washed immunoadsorbant
was then suspended in PBS with 0 02%
sodium azide and stored at 4°C. Before use
it was washed twice with 0-03M citrate
buffer (pH 2.5) and then with PBS.
Doubling dilutions of anti-TSG were
prepared in PBS with 0-0500 BSA in a
final volume of 0415 ml. Then, 0 05 ml of
labelled TSG (32,000 ct/min) and 0'05 ml
of PBS with 5% BSA were added. The
Serum TSG (ng/ml) 00 elevated
I TSG
<10 10-100 > 100 (>lO ng/ml)
87 3 0 3
0 0 15 100
7 18 3 75
16 23 9 67
38 5 2 1.5
28 4 0 12-5
37 2 1 7-5
33 1 0 3
45 1* 0 2
291 57 30
tubes were incubated at 4°C for 24 h in a
Rotamixer. After incubation and measure-
ment of the total amount of radioactivity
in each sample, 0-1 ml of anti-RGG
diluted 1:5 in PBS was added. The anti-
TSG-bound TSG was precipitated by anti-
RGG. The tubes were incubated at 20°C
for 4 h in a Rotamixer and centrifuged at
2000 g for 20 min. The supernatant was
removed by suction. The precipitate was
resuspended in 1 ml of PBS and re-
centrifuged in the same manner. After
removal of the supernatant, the radio-
activity of the tubes was assessed. Non-
specific radioactivity in control tubes was
about 1-1.500. An antibody concentration
(1:32,000), precipitating 5000 of the 1251-
TSG, was used for the subsequent con-
struction of inhibition curves.
The standard inhibition curve was con-
structed by diluting 0, 0.5, 1.0, 1.5, 3*0,
6-0, 12-0, 24-0, 48-0, 96-0, 192-0 and 384-0
ng per ml of a weighed amount of purified
TSG and of known immunodiffusion
TSG-positive sera in 0415 ml of PBS con-
taining 5% BSA. For the assay, reagents
were addied in the following order: (1)
0.15 ml anti-TSG appropriately diluted:
e.g. 1:32,000; (2) 0 05 ml 1251-TSG dilution
containing 32,000 ct/min; (3) 0*05 ml of
test serum sample or standard TSG; (4)
After 16 h of incubation at 20°C, 041 ml of
immunoadsorbant containing anti-RGG
was added and left to stand for 4 h in the
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TABLE II.-Serum TSG levels in gestational trophoblast tumours from different countries
Serum TSG (ng/ml) Elevated TSG
No. -n (> 10ng/ml)
Country patients <10 10-100 > 100 Total (%)
U.S.S.R., Moscow 35 10 19 6 25 (71)
France, Lyon 35 11 19 5 24 (69)
U.S.A., Bethesda 6 2 3 1 4 (67)
Total 76 2'3 41 12 53 (70)
Rotamixer; (5) 1 ml of PBS was added to
the test tubes before centrifugation. The
subsequent radioassay procedure was car-
ried out as described above. All serum
samples before assay were centrifuged and
decomplementated by heating at 56°C for
30 min.
The methods of immunoelectrophoresis
in agar, disc-electrophoresis, double
immunodiffusion in agar with standard
test system and immunoradioautography
for identification and titration of TSG,
have been reported in previous publica-
tions (Tatarinov & Masyukevich, 1970;
Tatarinov & Sokolov, 1977).
The circulating levels ofTSG in healthy
non-pregnant female and male donors fall
below 10 ng/ml in almost all cases, and in
58% were less than 3 ng/ml. Only 30o had
levels between 10 and 11 ng/ml. A cut-off
point of 10 ng/ml was therefore selected to
mark the upper limit of normal.
Elevated serum TSG levels in the range
10,000-320,000 ng/ml were demonstrated
in all 15 patients with hydatidiform moles.
TSG concentrations in these patients were
similar to those found in women during a
normal pregnancy. Raised serum TSG
levels were recorded in 7500 of patients
with post-molar trophoblast tumours, and
in 67% of patients with uterine chorio-
carcinomas (Table I). Circulating TSG
levels before the start of therapy ranged
from 50 to 16,000 ng/ml in most patients.
The incidence ofpathological levels in sera
from patients with trophoblast tumours
in different countries is similar (Table II).
Tables I and III show the occurrence of
elevated TSG levels in a variety of non-
trophoblast tumours. In 8% of cases with
non-trophoblast tumours, the circulating
TSG level was raised, but levels higher
56
TABLE III. Serurn TSG levels in some
non-trophoblastic tumours
Primary tumour site
Pathology
Testis
Malignant teratoma
Seminoma
Breast
Papilloma
Carcinoma
Colon
Adenocarcinoma
Bronchial
Carcinoma
Mediastinum
Teratoma
Serum TSG levels
(ng/ml)
390
600
57
20
16
14
150
11
11
12
24
14
12
18
24
than 100 ng/ml were rare (Tables I and
III).
The detection of TSG in the sera of
7000 ofpatients with gestational tropho-
blast tumours, including uterine chorio-
carcinomas, suggests that this immuno-
chemical test for TSG may have diagnostic
value. The correlation of TSG and human
chorionic gonadotrophin (hCG) release by
gestational trophoblast tumours has been
discussed by a number of authors
(Tatarinov et al., 1976; Bagshawe et al.,
1978; Searle et al., 1978; Seppala et al.,
1978; Than et al., 1979). From these data
it would be reasonable to assume that
TSG assays may play an ancillary role to
hCG assays for such lesions. However,
assays for TSG alone have an important
role in epidemiological investigations, par-
ticularly in population groups with a high
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risk of trophoblast disease (Tatarinov
et al., 1976).
The relationship of high serum TSG
levels to the function of the various histo-
logical subtypes of both choriocarcinomas
(Tatarinov et al., 1976; Zavadil, 1974) and
teratomas is now under active study.
High TSG levels in non-trophoblastic
tumours, particularly in breast and lung
carcinomas, might have an ectopic origin.
Ourresults agree with recent data concern-
ing the finding of TSG in non-trophoblast
tumours with or without the chorion
elements (Bagshawe et al., 1978; Johnson
et al., 1977; Wurz et al., 1979). TSG could
be a product of an activated placental
gene in malignant tissues, although this
seems to occur only in a very low percent-
age of non-trophoblast tumours.
In conclusion, the present test for TSG
has proved to be highly specific for tropho-
blast tumours, and may be used in its
differential diagnosis and possibly also in
epidemiological studies of post-molar
trophoblast disease.
The valuable help of Professor K. D. Bagshawe
and Drs D. M. Falaleeva, G. A. Kozjaeva, R. M.
Lequin, Ph. Sizaret, A. V. Sokolov and T. M.
Waldmann in the collaborative study for TSG is
greatly appreciated.
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